BioSpace News Archive

Zentalis® Pharmaceuticals, Inc. announced that on January 2, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 6,250 shares of the Company’s common stock to two newly hired employees.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m. ET.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), announces that George Ng, Chief Executive Officer, will present a corporate overview at the Biotech Showcase 2024.

Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024 at 2:15 p.m. ET.